Does fluoxetine (Prozac) cause hyponatremia?

Does Prozac Cause Hyponatremia?

Yes, Prozac (fluoxetine) can cause hyponatremia and this risk should be kept in mind when prescribing, particularly in elderly patients, those taking diuretics, or those who are volume depleted.

Understanding the Risk

The FDA drug label for Prozac explicitly warns that hyponatremia may occur as a result of treatment with SSRIs, including Prozac 1. In many cases, this appears to be the result of syndrome of inappropriate antidiuretic hormone secretion (SIADH), with cases of serum sodium lower than 110 mmol/L reported that were reversible when Prozac was discontinued 1.

The American College of Physicians clinical practice guideline acknowledges that hyponatremia is a potential adverse event with second-generation antidepressants, though evidence is described as "scarce" and should be "kept in mind" during treatment 2. A more recent guideline from the American Family Physician reports hyponatremia occurs in 0.5% to 12% in older adults, with an odds ratio of 3.3 (95% CI, 1.3 to 8.6) for SSRIs compared with other drug classes, typically within the first month of treatment 3.

Comparative Risk Among Antidepressants

Fluoxetine appears to have a moderate risk of hyponatremia compared to other antidepressants. Recent network meta-analysis data shows fluoxetine has an odds ratio of 3.40 (95% CI 1.13-10.21) for hyponatremia 4. This places it in the middle range—lower risk than venlafaxine (OR 5.99), paroxetine (OR 4.93), sertraline (OR 4.15), and escitalopram/citalopram (OR 3.49), but higher risk than mirtazapine (OR 2.83) 4.

Another large retrospective cohort study found that compared to sertraline as reference, fluoxetine did not show significantly different hyponatremia risk, while duloxetine and escitalopram showed higher risk, and bupropion and paroxetine showed lower risk 5.

Clinical Presentation and Timing

Hyponatremia typically develops within the first month of treatment, with most cases occurring within 2-3 weeks. In elderly patients specifically, hyponatremia was detected at a median of 13.5 days (range 4-64 days) after starting fluoxetine 6. The incidence in elderly patients was approximately 6.3 per 1000 treated per year with fluoxetine 6.

Signs and symptoms include:

• Headache, difficulty concentrating, memory impairment
• Confusion, weakness, unsteadiness leading to falls
• More severe cases: hallucination, syncope, seizure, coma, respiratory arrest, and death 1

High-Risk Populations

Elderly patients are at substantially greater risk 1. Additional risk factors include:

• Low body weight: Mean body weight in cases was 53.0 kg versus 64.5 kg in controls (P<0.01) 6
• Concurrent diuretic use 1
• Volume depletion from any cause 1
• Female gender (71% of cases versus 45% of controls, though confounded by body weight) 6

Clinical Management Algorithm

For patients starting fluoxetine:

1. Pre-treatment assessment:

   • Check baseline serum sodium
   • Identify high-risk features: age ≥65 years, body weight <55 kg, concurrent diuretics, volume depletion

2. Monitoring schedule:

   • High-risk patients: Check serum sodium at 1-2 weeks and 3-4 weeks after initiation
   • Standard-risk patients: Check serum sodium at 3-4 weeks
   • Monitor with any dose increase

3. If hyponatremia develops:

   • Serum sodium <125 mmol/L or symptomatic: Discontinue Prozac immediately and institute appropriate medical intervention 1
   • Serum sodium 125-130 mmol/L, asymptomatic: Consider discontinuation or close monitoring depending on clinical context
   • Serum sodium 130-135 mmol/L: Monitor more frequently

4. Alternative antidepressant selection in high-risk patients:

   • Consider mirtazapine (OR 2.83), which has lower hyponatremia risk 4
   • Consider bupropion, which showed protective effects in some studies 5
   • Avoid venlafaxine, which has the highest risk (OR 5.99) 4

Important Caveats

The hyponatremia is typically reversible upon discontinuation of fluoxetine 1. However, given fluoxetine's long half-life (4-6 days for parent drug, 4-16 days for active metabolite norfluoxetine), resolution may take longer than with shorter-acting SSRIs.

While the absolute incidence appears relatively low (approximately 0.5-1% overall, higher in elderly), the potential for severe complications including seizures, coma, and death makes vigilance essential, particularly during the first month of treatment.